Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.7 INR 3.24% Market Closed
Market Cap: 507.7m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

Operating Margin
Transgene Biotek Ltd

-543.5%
Current
-10 211%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-543.5%
=
Operating Profit
-10m
/
Revenue
1.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IN
Transgene Biotek Ltd
BSE:526139
507.7m INR
-543%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
28%
US
Amgen Inc
NASDAQ:AMGN
150.5B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-22%
Country IN
Market Cap 507.7m INR
Operating Margin
-543%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 320.1B USD
Operating Margin
28%
Country US
Market Cap 150.5B USD
Operating Margin
19%
Country US
Market Cap 120.4B USD
Operating Margin
40%
Country US
Market Cap 113.8B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 82.9B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.5B EUR
Operating Margin
-22%
No Stocks Found

Transgene Biotek Ltd
Glance View

Market Cap
507.7m INR
Industry
Biotechnology

Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. The company is headquartered in Medak, Telangana. The firm is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The firm offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. The company also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

TRABI Intrinsic Value
0.28 INR
Overvaluation 96%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-543.5%
=
Operating Profit
-10m
/
Revenue
1.8m
What is the Operating Margin of Transgene Biotek Ltd?

Based on Transgene Biotek Ltd's most recent financial statements, the company has Operating Margin of -543.5%.